Carter Keller

home / authors / carter-keller

Senior Vice President at Grifols and head of GigaGen.

Articles

GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B

GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B

Sophia Abene;Carter Keller
November 25th 2024

Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.

Read More

GigaGen's New Contract with BARDA for Polyclonal Antibody Development

GigaGen's New Contract with BARDA for Polyclonal Antibody Development

Sophia Abene;Carter Keller
October 4th 2024

Carter Keller discusses the company's recent $135.2 million contract with BARDA to develop recombinant polyclonal antibody therapies targeting botulinum neurotoxins and an unspecified biothreat, highlighting their innovative approach to address emerging health threats.

Read More

HBV Antibody GIGA-2339 Cleared for Clinical Trials to Address Hepatitis B Cure Gap

HBV Antibody GIGA-2339 Cleared for Clinical Trials to Address Hepatitis B Cure Gap

Sophia Abene;Carter Keller
Published: August 12th 2024 | Updated: August 12th 2024

Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B.

Read More

Latest Updated Articles

Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Will the Melting Permafrost Uncover Vector Borne and Zoonotic Pathogens and Release Ancient Infectious Diseases?
Published: November 28th 2024 | Updated: December 3rd 2024
Will the Melting Permafrost Uncover Vector Borne and Zoonotic Pathogens and Release Ancient Infectious Diseases?
Treatment Considerations for Empiric Therapy
Published: November 25th 2024 | Updated: December 3rd 2024
Treatment Considerations for Empiric Therapy
GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B
Published: November 25th 2024 | Updated: December 3rd 2024
GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis B
Considering a Beta Lactam as Adjunctive Therapy for Staphylococcus aureus Early in Treatment
Published: November 25th 2024 | Updated: December 3rd 2024
Considering a Beta Lactam as Adjunctive Therapy for Staphylococcus aureus Early in Treatment
First Case of Clade I Mpox Diagnosed in the US
Published: November 20th 2024 | Updated: December 3rd 2024
First Case of Clade I Mpox Diagnosed in the US
© 2024 MJH Life Sciences

All rights reserved.